Death from melanoma over the next several decades should stabilize and then decline in light-skinned populations, according to study results.
MRV Research
NRAS Mutations May Serve as Efficacy Biomarker for Immunotherapies in Melanoma
Patients with NRAS-mutated melanoma had better responses and improved treatment outcomes compared with those who did not harbor the mutation, according to a recent retrospective study published in Cancer Immunology Research
Macrophages – The Missing Link in Melanoma Resistance to BRAF Therapy
In a new study entitled “BRAF Inhibition Stimulates Melanoma-Associated Macrophages to Drive Tumor Growth,” researchers suggest that a specific type of immune cell — macrophages — offers a potential new therapeutic target in patients with melanoma resistance to BRAF inhibitors. The study was published in the journal Clinical Cancer Research.
Zeroing In on Macrophages to Unravel Melanoma Resistance to BRAF Inhibitors
Scientists at the Wistar Institute say they have discovered one way in which melanoma becomes resistant to a particular form of targeted therapy. They believe an understanding this phenomenon may lead to a new melanoma target or prompt new designs of these treatments.